CUBIST Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CUBIST, and what generic alternatives to CUBIST drugs are available?
CUBIST has seven approved drugs.
There are thirty US patents protecting CUBIST drugs.
There are three hundred and forty-two patent family members on CUBIST drugs in fifty-three countries and fifty-five supplementary protection certificates in eighteen countries.
Summary for CUBIST
International Patents: | 342 |
US Patents: | 30 |
Tradenames: | 6 |
Ingredients: | 5 |
NDAs: | 7 |
PTAB Cases with CUBIST as patent owner: | See PTAB cases with CUBIST as patent owner |
Drugs and US Patents for CUBIST
Expired US Patents for CUBIST
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Cubist Pharms Llc | CUBICIN | daptomycin | POWDER;INTRAVENOUS | 021572-002 | Sep 12, 2003 | 8,129,342 | ⤷ Try a Trial |
Cubist Pharms Llc | CUBICIN | daptomycin | POWDER;INTRAVENOUS | 021572-001 | Sep 12, 2003 | 6,468,967 | ⤷ Try a Trial |
Cubist Pharms | ENTEREG | alvimopan | CAPSULE;ORAL | 021775-001 | May 20, 2008 | 6,469,030 | ⤷ Try a Trial |
Cubist Pharms | ENTEREG | alvimopan | CAPSULE;ORAL | 021775-001 | May 20, 2008 | 5,250,542 | ⤷ Try a Trial |
Cubist Pharms Llc | CUBICIN | daptomycin | POWDER;INTRAVENOUS | 021572-002 | Sep 12, 2003 | 6,852,689 | ⤷ Try a Trial |
Cubist Pharms Llc | CUBICIN | daptomycin | POWDER;INTRAVENOUS | 021572-001 | Sep 12, 2003 | 5,912,226 | ⤷ Try a Trial |
Cubist Pharms Llc | CUBICIN | daptomycin | POWDER;INTRAVENOUS | 021572-001 | Sep 12, 2003 | 6,852,689 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for CUBIST drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Capsules | 12 mg | ➤ Subscribe | 2017-06-16 |
➤ Subscribe | For Injection | 500 mg/vial | ➤ Subscribe | 2008-11-19 |
➤ Subscribe | Tablets | 200 mg | ➤ Subscribe | 2015-05-27 |
International Patents for CUBIST Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
China | 110204558 | ⤷ Try a Trial |
Cyprus | 1121284 | ⤷ Try a Trial |
Japan | 5734545 | ⤷ Try a Trial |
Australia | 2004299413 | ⤷ Try a Trial |
Peru | 20120585 | ⤷ Try a Trial |
Moldova, Republic of | 4588 | ⤷ Try a Trial |
Colombia | 6541585 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for CUBIST Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1539977 | SPC/GB15/020 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: FIDAXOMICIN; REGISTERED: UK EU/1/11/733/001 20111207; UK EU/1/11/733/002 20111207; UK EU/1/11/733/003 20111207; UK EU/1/11/733/004 20111207 |
1539977 | 92684 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: FIDAXOMICINE OU SON SEL PHARMACEUTIQUEMENT ACCEPTABLE; AUTHORISATION NUMBER AND DATE: EU/1/11/733/001-002-004 - DIFICLIR |
1556389 | CR 2016 00004 | Denmark | ⤷ Try a Trial | PRODUCT NAME: CEFTOLOZAN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, SAERLIGT ET SVOVLSYRESALT; REG. NO/DATE: EU/1/15/1032/001 20150922 |
1556389 | 1690003-7 | Sweden | ⤷ Try a Trial | PRODUCT NAME: CEFTOLOZAN ELLER ETT FARMACEUTISKT ACCEPTABELT SALT DAERAV, SPECIELLT ETT SVAVELSYRASALT; REG. NO/DATE: EU/1/15/1032 20150918 |
1115417 | 22/2006 | Austria | ⤷ Try a Trial | PRODUCT NAME: DAPTOMYCIN; REGISTRATION NO/DATE: EU/1/05/328/001 UND 002 20060119 |
1699784 | 132016000024232 | Italy | ⤷ Try a Trial | PRODUCT NAME: TEDIZOLID, FACOLTATIVAMENTE IN FORMA DI ESTERE, IN PARTICOLARE UN FOSFATO, O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(SIVEXTRO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/15/991/001, 20150325 |
1115417 | SPC/GB06/024 | United Kingdom | ⤷ Try a Trial | SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB06/024 GRANTED TO CUBIST PHARMACEUTICALS, INC IN RESPECT OF THE PRODUCT DAPTOMYCIN, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6162 DATED 27 JUNE 2007 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 22 JANUARY 2021. |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.